A Multicenter, Open-label, Phase I/Ⅱ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFS101A in Combination With Toripalimab Treating Patients With Advanced Solid Tumors
Latest Information Update: 26 May 2022
At a glance
- Drugs GFS 101 (Primary) ; Toripalimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors GenFleet Therapeutics
Most Recent Events
- 16 May 2022 Status changed from not yet recruiting to withdrawn prior to enrolment, because the sponsor decided to withdraw the study.
- 29 Dec 2021 New trial record